Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27964705
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Curr+Neuropharmacol
2017 ; 15
(7
): 938-950
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Biological Drugs in Guillain-Barré Syndrome: An Update
#MMPMID27964705
Motamed-Gorji N
; Matin N
; Tabatabaie O
; Pavone P
; Romano C
; Falsaperla R
; Vitaliti G
Curr Neuropharmacol
2017[]; 15
(7
): 938-950
PMID27964705
show ga
BACKGROUND: Guillain-Barré Syndrome (GBS) is currently considered the most common
global cause of acute flaccid paralysis. Currently, standard therapy for
Guillain-Barré Syndrome includes intravenous immunoglobulin or plasma exchange.
Despite medical advances regarding these treatments, many treated patients do not
reach full recovery. Therefore several biological agents have attracted the
attentions from researchers during the last decades, and various studies have
investigated their role in Guillain-Barré Syndrome. OBJECTIVE: The present study
aims to address emerging biological approaches to GBS while considering their
efficiency and safety in treating the disease. MATERIALS AND METHODS: An
extensive electronic literature search was conducted by two researchers from
April 2016 to July 2016. Original articles, clinical trials, systematic reviews
(with or without meta-analysis) and case reports were selected. Titles and
abstracts of papers were screened by reviewers to determine whether they met the
eligibility criteria, and full texts of the selected articles were retrieved.
RESULTS: Herein authors focused on the literature data concerning emerging
biological therapeutic agents, namely anti-C5 monoclonal antibody (Eculizumab),
anti-C1q monoclonal antibody, anti-T cell monoclonal antibody, anti-CD2
monoclonal antibody, anti L-selectin monoclonal antibody, anti- CD20 monoclonal
antibody (Rituximab), anti-CD52 monoclonal antibody (Alemtuzumab) and cytokine
targets. By far, none of these agents have been approved for the treatment of GBS
by FDA. CONCLUSION: Literature findings represented in current review herald
promising results for using these biological targets. Current review represents a
summary of what is already in regards and what progress is required to improve
the immunotherapeutic approach of treating GBS via future studies.
free
free
free
